fda warning letter glp-1 october 2025 CDER Letters Jump 50% in FY — What That Means for Industry FDA issued 25 warning letters

Gastrointestinal Protection: Extensive research has been conducted on the effects of BPC-157 on the GI system

Overall, when used in appropriate patients under medical supervision, sermorelin is typically well tolerated, and serious adverse effects are rare

Based on the aforementioned mechanisms, researchers have applied small molecules to modulate epigenetic profiles in somatic cells and thus to promote somatic reprogramming into hepatocytes bypassing the iPSC stage (Table 1 and 2)

Visible density changes typically appear in 6 to 12 weeks, with continued improvement over 3 to 6 months

The quick answer: Semaglutide is a GLP-1 receptor agonist an injectable (and now oral) drug FDA-approved for long-term, chronic weight management , producing the larger weight loss but at meaningfully higher cost